Focused on novel, nanotechnology-based therapeutics

Oliver Fetzer, Ph.D.
President and Chief Executive Officer

David P. DeMagistris, Ph.D.
Senior Vice President, Pharmaceutical Sciences and Manufacturing

Scott Eliasof, Ph.D.
Senior Director, Research

Alexandra Glucksmann, Ph.D.
Senior Vice President, Research and Business Operations

Karen Roberts
Senior Vice President, Finance and Administration

John Ryan, Ph.D., M.D.
Senior Vice President and Chief Medical Officer

John brings to Cerulean twenty years of clinical development experience. He was most recently Chief Medical Officer at Aveo Pharmaceuticals, an oncology biotherapeutics company in Cambridge, Massachusetts. While at Aveo, he established and built the Clinical Development organization, which has since successfully advanced several programs into Phase 3 development. John began his drug development career at Merck Research Laboratories, where he was Executive Director of Clinical Development in Vaccines and Infectious Diseases. He later joined Wyeth as Senior Vice President of Translational Medicine and became Senior Vice President of Clinical Research of Wyeth and Genetics Institute. John has led the development efforts of several programs from Phase 1 through registration at Merck, Genetics Institute, and Wyeth.

John received his Ph.D. from Yale University and his M.D. from the University of California in San Diego and was on the faculty of the Department of Internal Medicine at Yale Medical School for over ten years.

Jean Silveri, J.D.
Senior Vice President, General Counsel

Marc Wolfgang
Senior Director, Pharmaceutical Sciences and Manufacturing

Cissy Young, Ph.D.
Director, Strategy and Business Development